Advertisement

Molecular Medicine

, Volume 20, Issue 1, pp 80–92 | Cite as

Kisspeptin Effect on Endothelial Monocyte Activating Polypeptide II (EMAP-II)-Associated Lymphocyte Cell Death and Metastases in Colorectal Cancer Patients

  • Martha Stathaki
  • Athanasios Armakolas
  • Andreas Dimakakos
  • Loukas Kaklamanis
  • Ioannis Vlachos
  • Manoussos M. Konstantoulakis
  • George Zografos
  • Michael Koutsilieris
Research Article

Abstract

Kisspeptin is an antimetastatic agent in some cancers that has also been associated with lymphoid cell apoptosis, a phenomenon favoring metastases. Our aim was to determine the association of kisspeptin with lymphocyte apoptosis and the presence of metastases in colorectal cancer patients. Blood was drawn from 69 colon cancer patients and 20 healthy volunteers. Tissue specimens from healthy and pathological tissue were immunohistochemically analyzed for kisspeptin and endothelial monocyte activating polypeptide II (EMAP-II) expression. Blood EMAP-II and soluble Fas ligand (sFasL) levels were examined by an enzyme-linked immunosorbent assay method. The kisspeptin and EMAP-II expression and secretion levels in the DLD-1 and HT-29 colon cancer cell lines were examined by quantitative real-time polymerase chain reaction, Western analysis and enzyme-linked immunosorbent assay, whereas lymphocyte viability was assessed by flow cytometry. The effect of kisspeptin on the viability of colon cancer cells was examined by MTT [3-(4),5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. Exogenous, synthetic and naturally produced, kisspeptin induces through the G-protein-coupled receptor 54 (GPR54; also known as the kisspeptin receptor) the EMAP-II expression and secretion in colon cancer cell lines, inducing in vitro lymphocyte apoptosis, as verified by the use of an anti-EMAP-II antibody. These results were reversed with the use of kisspeptin inhibitors and by kisspeptin-silencing experiments. Tumor kisspeptin expression was associated with the tumor EMAP-II expression (p < 0.001). Elevated kisspeptin and EMAP-II expression in colon cancer tissues was associated with lack of metastases (p < 0.001) in colon cancer patients. These data indicate the antimetastatic effect of tumor-elevated kisspeptin in colon cancer patients that may be mediated by the effect of kisspeptin on EMAP-II expression in colon cancer tumors in patients with normal serum EMAP-II levels. These findings provide new insight into the role of kisspeptin in the context of metastases in colon cancer patients.

References

  1. 1.
    Jemal A, et al. (2008) Cancer statistics. CA Cancer J. Clin. 58:71–96.CrossRefPubMedGoogle Scholar
  2. 2.
    Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. (2006) Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies. Br. J. Cancer. 94:982–99.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Meulenbeld HJ, Creemers GJ. (2007) First-line treatment strategies for elderly patients with metastatic colorectal cancer. Drugs Aging. 24:223–38.CrossRefPubMedGoogle Scholar
  4. 4.
    Gatta G. (1998) Survival of colorectal cancer patients in Europe during the period 1978–1989. Eur. J. Cancer. 34:2176–83.CrossRefPubMedGoogle Scholar
  5. 5.
    Edge SB, et al. (eds.). (2010) AJCC Cancer Staging Manual. 7th edition. New York: Springer. 649 pp.Google Scholar
  6. 6.
    Whiteside TL. (2002) Apoptosis of immune Whiteside cells in tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine. 20:A46–51.CrossRefPubMedGoogle Scholar
  7. 7.
    Strehl J, et al. (2010) Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases. BMC Cancer. 10:82.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Ehrenschwender M, Wajant H. (2009) The role of FasL and Fas in health and disease. Adv. Exp. Med. Biol. 647:64–93.CrossRefPubMedGoogle Scholar
  9. 9.
    Murray JC, et al. (2004) Colorectal cancer cells induce lymphocyte apoptosis by an endothelial monocyte-activating polypeptide-II-dependent mechanism. J. Immunol. 172:274–81.CrossRefPubMedGoogle Scholar
  10. 10.
    Soufir N, Grandchamp B, Basset-Seguin N. (2009) New trends in the susceptibility to melanoma. Cancer Treat. Res. 146:213–23.CrossRefPubMedGoogle Scholar
  11. 11.
    Schwarz RE, Awasthi N, Konduri S. (2010) Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation. Cancer Biol. Ther. 9:632–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Awasthi N, Schwarz MA, Verma V, Cappiello C, Schwarz RE. (2009) Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signalling. Lab. Invest. 89:38–46.CrossRefPubMedGoogle Scholar
  13. 13.
    Reznikov AG, Chaykovskaya LV, Polyakova LI, Kornelyuk AI. (2007) Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model. Exp. Oncol. 29:267–71.PubMedGoogle Scholar
  14. 14.
    Van Horssen R, Eggermont AM, Ten Hagen TL. (2006) Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev. 17:339–48.CrossRefPubMedGoogle Scholar
  15. 15.
    Murray JC, et al. (2004) Endothelial monocyte activating polypeptide II (EMAP-II) a novel inducer of lymphocyte apoptosis. J. Leuc. Biol. 75:772–6.CrossRefGoogle Scholar
  16. 16.
    Waters JP, Pober JS, Bradley JR. (2013) Tumour necrosis factor and cancer. J. Pathol. 230:241–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Liu K. (2010) Role of apoptosis resistance in immune evasion and metastasis of colorectal cancer. World J. Gastrointest. Oncol. 2:399–406.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Makri A, Pissimissis N, Lembessis P, Polychronakos C, Koutsilieris M. (2008) The kisspeptin (KiSS-1)/GPR54 system in cancer biology. Cancer Treat. Rev. 34:682–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Navenot J-M, Fujii N, Peiper SC. (2009) SS1 metastasis suppressor gene product induces suppression of tyrosine kinase receptor signaling to Akt, tumor necrosis factor family ligand expression, and apoptosis. Mol. Pharmacol. 75:1074–83.CrossRefPubMedGoogle Scholar
  20. 20.
    Ohtaki T, et al. (2001) Metastasis suppressor gene kiss-1 encodes peptide ligand of a G-protein-coupled receptor. Nature. 411:613–617.CrossRefPubMedGoogle Scholar
  21. 21.
    Muir AI, et al. (2001) AXOR12, a novel human G protein-coupled receptor, activated by the peptide kiss-1. J. Biol. Chem. 276:28969–97.CrossRefPubMedGoogle Scholar
  22. 22.
    Cho SG, Li D, Tan K, Siwko SK, Liu M. (2012) KiSS1 and its G-protein-coupled receptor GPR54 in cancer development and metastasis. Cancer Metastasis Rev. 31:585–91.CrossRefPubMedGoogle Scholar
  23. 23.
    Armakolas A, et al. (2010) Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate: evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells. Prostate. 70:1233–42.CrossRefGoogle Scholar
  24. 24.
    Papageorgiou E, Pitulis N, Manoussakis M, Lembessis P, Koutsilieris M. (2008) Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells. Mol. Med. 14:403–11.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Battersby S, Boddy CS, Critchley ODH, Jabbour NH. (2002) Expression and localization of endothelial monocyte-activating polypeptide II in the human endometrium across the menstrual cycle: regulation of expression by prostaglandin E2. J. Clin. Endocrinol. Metab. 87:3928–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Bas A, Forsberg G, Hammarstrom S, Hammarstrom M.-L. (2004) Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. Scand. J. Immunol. 59:566–73.CrossRefPubMedGoogle Scholar
  27. 27.
    Kostakis ID, et al. (2013) KISS1 expression in colorectal cancer. APMIS. 121:1004–10.CrossRefPubMedGoogle Scholar
  28. 28.
    Song E, et al. (2001) Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br. J. Cancer. 85:1047–54.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Curtis AE, et al. (2010) Kisspeptin is released from human prostate cancer cell lines but plasma kisspeptin is not elevated in patients with prostate cancer. Oncol. Rep. 23:1729–34.PubMedGoogle Scholar
  30. 30.
    Micheau O, Tschopp J. (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 114:181–90.CrossRefPubMedGoogle Scholar
  31. 31.
    Boroumand-Noughabi S, et al. (2010) Soluble Fas might serve as a diagnostic tool for gastric adenocarcinoma. BMC Cancer. 10:275.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Bottoni A, et al. (2007) Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines. J. Cell. Physiol. 212:293–7.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Martha Stathaki
    • 1
    • 2
  • Athanasios Armakolas
    • 2
    • 4
  • Andreas Dimakakos
    • 2
  • Loukas Kaklamanis
    • 3
  • Ioannis Vlachos
    • 2
  • Manoussos M. Konstantoulakis
    • 1
  • George Zografos
    • 1
  • Michael Koutsilieris
    • 2
  1. 1.First Propadeutic Surgical Clinic, Athens Medical SchoolNational and Kapodestrian University of AthensAthensGreece
  2. 2.Physiology Laboratory, Athens Medical SchoolNational and Kapodestrian University of AthensAthensGreece
  3. 3.Department of PathologyOnasio HospitalAthensGreece
  4. 4.Department of Experimental PhysiologyAthensGreece

Personalised recommendations